Vivos Therapeutics Inc. (VVOS), a prominent name in the US stocks market, has been under the spotlight recently. This leading medical technology company has been making waves with its innovative diagnostic and treatment methods for patients grappling with various health conditions.
Many of these conditions are associated with breathing-related sleep disorders emerging from certain dentofacial abnormalities.
In the pre-market session today, Vivos Therapeutics Inc. (VVOS) showcased remarkable stock performance, with its price surging to $0.28, reflecting a substantial change of 51.46%.
This substantial uptick in price was accompanied by robust trading activity, as the trading volume reached a significant 11,390,000 shares. These noteworthy market movements have undoubtedly captured the attention of investors, signaling potential market enthusiasm and heightened anticipation for the trading day ahead.
Recent Happenings
October 4, 2023, Vivos Therapeutics has announced forging strategic collaborations and agreements that not only expand its product line but also create promising revenue opportunities.
The company publicized two key strategic agreements, which are expected to add potentially significant new revenue opportunities for Vivos, as well as airway-focused expertise and potential cost savings for Vivos-trained providers.
Collaborations with Ormco and On Demand Orthodontist
One of these collaborations involves Ormco, a division of publicly-traded Envista Holdings Corporation, and On Demand Orthodontist (ODO).
Ormco, recognized for its exceptional products and customer service, has helped doctors treat more than 20 million patients in over 140 countries. Their Spark™ Clear Aligners are rapidly becoming the go-to clear aligner of choice for orthodontic specialists.
As part of this agreement, Vivos and Ormco will embark on joint marketing and sales support from each company’s field sales teams. This is expected to facilitate faster treatment times and improved predictability for positive clinical outcomes for Vivos patients using Vivos CARE devices with Spark Aligners.
The new agreement with ODO, on the other hand, provides a service to Vivos providers featuring direct access and case collaboration with airway-focused orthodontic specialists who are available to help optimize clinical outcomes for Vivos cases.
The Way Forward for Vivos Therapeutics
Despite the challenges posed by the larger economic and market environment, Vivos Therapeutics has positioned itself to achieve revenue growth and, ultimately, cash flow positive operations and profitability in the foreseeable future.
With their innovative, evidence-based technology and a network of trained providers, they remain committed to their core mission of addressing the crisis of sleep apnea and breathing-related sleep issues. This makes Vivos a key player to watch in the US stocks market.
